Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: Cyclosporine versus sirolimus

Transplantation Proceedings

Volumn 45, Issue 3, 2013, Pages 1149-1156

  Sereno, J ^a   Parada, B ^a,b   Rodrigues Santos, P ^c   Lopes, P C ^c   Carvalho, E ^c,d   Vala, H ^e   Teixeira Lemos, E ^a,e   Alves, R ^b   Figueiredo, A ^b   Mota, A ^b   Teixeira, F ^a   Reis, F ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d The Portuguese Diabetes Association (APDP)   (Portugal)

^e POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; CYCLINE; CYCLOSPORIN A; EOSIN; GLUCOSE; HEMATOXYLIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NITROGEN; PROTEIN P53; RAPAMYCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CONFERENCE PAPER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HEART RATE; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE STRUCTURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CYCLOSPORINE; HEART RATE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; RATS; RATS, WISTAR; SIROLIMUS;

EID: 84876882818     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.02.085     Document Type: Conference Paper

References (45)

1. D. Colombo, E. Ammirati Cyclosporine in transplantation - a history of converging timelines J Biol Regul Homeost Agents 25 4 2011 493 504
2. F. Moreso, M. Ibernon, M. Gomà Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss Am J Transplant 6 4 2006 747 752 (Pubitemid 43345012)
3. B.J. Nankivell, J.R. Chapman Chronic allograft nephropathy: current concepts and future directions Transplantation 81 5 2006 643 654
4. D. Cattaneo, N. Perico, F. Gaspari Nephrotoxic aspects of cyclosporine Transplant Proc 36 2004 234S 239S (Pubitemid 38373868)
5. S.C. Textor, S.J. Taler, V.J. Canzanello Post-transplantation hypertension related to calcineurin inhibitors Liver Transpl 6 5 2000 521
6. K.C. Mange, B. Cizman, M. Joffe Arterial hypertension and renal allograft survival JAMA 283 2000 633 638 (Pubitemid 30069179)
7. A. Mota Sirolimus: a new option in transplantation Expert Opin Pharmacother 6 3 2005 479 487 (Pubitemid 40521084)
8. A. Mota, M. Arias, E.I. Taskinen Rapamune Maintenance Regimen Trial Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years Am J Transplant 4 6 2004 953 961 (Pubitemid 38745595)
9. J.M. Campistol, P. Cockwell, F. Diekmann Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation Transpl Int 22 7 2009 681 687
10. S. Merkel, N. Mogilevskaja, M. Mengel Side effects of sirolimus Transplant Proc 38 3 2006 714 715
11. G.K. Rangan Sirolimus-associated proteinuria and renal dysfunction Drug Saf 29 12 2006 1153 1161 (Pubitemid 44904830)
12. S.J. Tomlanovich, F. Vincenti Sirolimus: defining nephrotoxicity in the renal transplant recipient Clin J Am Soc Nephrol 2 2007 198 199
13. H.P. Marti, F.J. Frey Nephrotoxicity of rapamycin: an emerging problem in clinical medicine Nephrol Dial Transplant 20 1 2005 13 15 (Pubitemid 40207602)
14. M. Boratyńska, M. Banasik, E. Watorek Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients Transplant Proc 38 1 2006 101 104
15. J.R. Chapman Chronic calcineurin inhibitor nephrotoxicity-lest we forget Am J Transplant 11 4 2011 693 697
16. F. Reis, P. Tavares, L.C. Rito Platelet activation is increased in cyclosporin A-induced hypertensive rats J Cardiovasc Pharmacol 36 1 2000 56 64 (Pubitemid 30419123)
17. F. Reis, P. Rocha-Pereira, E. Teixeira de Lemos Oxidative stress in cyclosporin-induced hypertension: evidence of beneficial effects or tolerance development with nitrate therapy Transplant Proc 39 8 2007 2494 2500 (Pubitemid 47588361)
18. F. Reis The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option Kidney Int 77 12 2010 1055 1057
19. Luo L, Sun Z, Luo G. Rapamycin is less fibrogenic than cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy [e-pub ahead of print]. J Surg Res. Accessed March 17, 2002
20. G. Chen, H. Chen, C. Wang Kapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts PLoS One 7 3 2012 e33626
21. G. Stallone, B. Infante, A. Schena Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients J Am Soc Nephrol 16 12 2005 3755 3762 (Pubitemid 46211299)
22. V. Bumbea, N. Kamar, D. Ribes Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 11 2005 2517 2523 (Pubitemid 41548881)
23. A.M. Teixeira, P. Garrido, P. Santos Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure Ren Fail 32 9 2010 1073 1080
24. W. Zhang, R.G. Victor Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension Am J Hypertens 13 9 2000 999 1004
25. F. Reis, B. Parada, E. Lemos, P. Garrido Hypertension induced by immunosuppressive drugs - comparative analysis between Sir and CsA Transplant Proc 41 3 2009 868 873
26. M.V. Blagosklonny Rapamycin-induced glucose intolerance: hunger or starvation diabetes Cell Cycle 10 24 2011 4217 4224
27. E. Gyurus, Z. Kaposztas, B.D. Kahan Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens Transplant Proc 43 5 2011 1583 1592
28. M.J. Pereira, J. Palming, M. Rizell The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipocytes Mol Cell Endocrinol 365 2 2013 260 269
29. V.P. Houde, S. Brûlé, W.T. Festuccia, P.G. Blanchard, K. Bellmann, Y. Deshaies, A. Marette Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue Diabetes 59 6 2010 1338 1348
30. J. Moro, L. Almenar, L. Martínez-Dolz mTOR inhibitors: do they help preserve renal function? Transplant Proc 39 7 2007 2135 2137 (Pubitemid 47418173)
31. G.S. Jensen, A. Wiseman, J.F. Trotter Sirolimus conversion for renal preservation in liver transplantation: not so fast Liver Transpl 14 5 2008 601 603 (Pubitemid 351696269)
32. D. DuBay, R.J. Smith, K.G. Qiu Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 5 2008 651 659 (Pubitemid 351696277)
33. P. Cravedi, P. Ruggenenti, G. Remuzzi Sirolimus to replace calcineurin inhibitors? Too early yet Lancet 373 9671 2009 1235 1236
34. R.J. Knight, B.D. Kahan The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int 70 6 2006 994 999 (Pubitemid 44344067)
35. S. Bunnapradist, F. Vincenti Transplantation: to convert or not to convert: lessons from the CONVERT trial Nat Rev Nephrol 5 7 2009 371 373
36. F.P. Schena, M.D. Pascoe, J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transpjantation 87 2 2009 233 242
37. R.K. Wali, M.R. Weir Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 13 6 2008 614 621
38. A.V. Mulay, S. Cockfield, R. Stryker, D. Fergusson, G.A. Knoll Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence Transplantation 82 9 2006 1153 1162 (Pubitemid 44748017)
39. M. Laplante, D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2 2012 274 293
40. S. Krämer, Y. Wang-Rosenke, V. Scholl Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat Am J Physiol Renal Physiol 294 2 2008 F440 F449
41. W. Lieberthal, J.S. Levine The role of the mammalian target of rapamycin (mTOR) in renal disease J Am Soc NephroI 20 12 2009 2493 2502
42. G. Chen, H. Chen, C. Wang Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts PLoS One 7 3 2012 e33626
43. M. Naesens, D.R. Kuypers, M. Sarwal Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 2 2009 481 508
44. C. Li, C.W. Yang The pathogenesis and treatment of chronic allograft nephropathy Nat Rev Nephrol 5 9 2009 513 519
45. J.W. Park, E.H. Bae, I.J. Kim Paricalcitol attenuates cyclosporine-induced kidney injury in rats Kidney Int 77 12 2010 1076 1085